Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 3E99M | IM / RA |
female patient was accidentally administered a 3rd dose of Menveo vaccine; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 40-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 3E99M, expiry date 31-DEC-2025) for prophylaxis. Previously administered products included Menveo (1st dose on 15th November 2024). Concomitant products included Meningococcal vaccine A/C/Y/W conj (CRM197) (Menveo). On 06-FEB-2025, the patient received Menveo (intramuscular, right deltoid) .5 ml. On 06-FEB-2025, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: female patient was accidentally administered a 3rd dose of Menveo vaccine). On 06-FEB-2025, the outcome of the extra dose administered was not applicable. It was unknown if the reporter considered the extra dose administered to be related to Menveo. It was unknown if the company considered the extra dose administered to be related to Menveo. Additional Information: GSK receipt date: 19-MAR-2025 The reporter stated that a female patient was accidentally administered a 3rd dose of Menveo vaccine on February 6th, 2025, in the right deltoid due to a charting error, which led to extra dose administered; the 2nd dose was not documented in the chart, The HCP reported that the patient was administered the 1st dose of Menveo on November 15, 2024, and the 2nd dose on January 15th, 2025. The HCP reported as medical history for this patient that she does not have a spleen.
MENVEO